Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | LCK | P06239 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25863102 | 0.86 | ATR (0.36) | ATRCA1CA2TAS1R3TAS1R1 | |
| SCHEMBL31290291 | 0.75 | CTSS (0.42) | ATRCA1CA2CYP17A1 | |
| SCHEMBL8321546 | 0.73 | ATR (0.32) | ATRLCK | |
| SCHEMBL20865565 | 0.72 | ATR (0.40) | ATRCA1CA2CYP17A1LCK | |
| SCHEMBL25829865 | 0.70 | ATR (0.41) | ATRCA1CA2CYP17A1CA12 | |
| SCHEMBL25255238 | 0.70 | GPR35 (0.36) | ATR | |
| SCHEMBL25863135 | 0.70 | GPR35 (0.36) | ATR | |
| SCHEMBL29140715 | 0.69 | ATR (0.36) | ATRCA1CA2SYKCYP17A1 | |
| SCHEMBL31124503 | 0.69 | CA1 (0.39) | ATRCA1CA2SYKCYP17A1 | |
| SCHEMBL25829765 | 0.69 | ATR (0.37) | ATRCA1CA2CYP17A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234922-A1 | PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID | ENANTA PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234922-A1 | PROCESSES FOR THE PREPARATION OF 4,6,7-TRIFLUORO-1H-INDOLE-2-CARBOXYLIC ACID | ACE2, HTR3C, SARS1 | ATR 2583/4885CA1 2017/4885CA2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.